Using RBOs and Megafunds to Hedge Longevity Risk and Specialty Drug Costs

Thank you for your interest in spreading the word on The Journal of Alternative Investments.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.